Bausch + Lomb is set to present a series of scientific data and analyses at the upcoming American Society of Cataract and Refractive Surgery meeting, highlighting advancements in eye care technology and treatment.
In an exciting leap forward within the realm of ophthalmology, Bausch + Lomb, a global leader in eye health, has announced their agenda for the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held in Boston from April 5-8, 2024. The company is slated to present a series of robust scientific data and analyses through fifteen podium and four poster presentations, spotlighting advancements across a broad spectrum of their product portfolio. These will include the TENEO™ Excimer Laser Platform, MIEBO® (Perfluorohexyloctane Ophthalmic Solution), and intraocular lenses (IOLs): enVista® Envy* and IC-8® Apthera™, painting a picture of innovation and precision in eye care solutions.
Among the distinguished developments is the TENEO™ Excimer Laser Platform, approved by the FDA and representing the first of its kind in nearly two decades. This platform heralds a new era in LASIK surgery, potentially setting new benchmarks in accuracy, efficiency, and user experience. It demonstrates Bausch + Lomb’s commitment to incorporating cutting-edge technology in their offerings.
Dry eye disease, a condition that can significantly impact quality of life, is in the spotlight with the introduction of MIEBO® (Perfluorohexyloctane Ophthalmic Solution). This innovative solution is under evaluation for its efficacy in treating the signs and symptoms associated with this prevalent eye condition. The unique formulation of MIEBO® symbolizes a potential shift in managing dry eye disease, emphasizing patient comfort and sustained relief.
Furthermore, the IOLs like enVista® Envy and IC-8® Apthera™ are set to redefine visual outcomes in cataract and refractive surgery. These lenses are designed to enhance visual acuity and offer solutions for patients seeking spectacle independence. enVista® Envy, pending FDA approval, along with IC-8® Apthera™, underline Bausch + Lomb’s focus on innovation to address the spectrum of visual needs across different patient demographics, including those with complex ophthalmic profiles.
Adding to the scientific dissemination at the ASCRS meeting, Bausch + Lomb will also sponsor educational events. These sessions are geared towards fostering a deeper understanding of their products, including the dry eye disease treatments MIEBO® and XIIDRA® (lifitegrast ophthalmic solution) 5%, and sharing insights into the refractive surgery advancements offered by the TENEO™ platform and the novel IOLs. These forums provide a platform for interactive learning and demonstrate the company’s dedication to supporting the professional development of healthcare providers in the ophthalmic community.
Bausch + Lomb’s comprehensive involvement at the ASCRS annual meeting is a testament to their enduring commitment to advancing eye health. Through the unveiling of new scientific data and hosting educational forums, the company continues to anchor its position as a beacon of innovation in the eye care industry. The outcomes of these presentations and discussions are eagerly anticipated, with potential implications for patient care standards and the future trajectory of ophthalmic treatment and technology.
It is evident that Bausch + Lomb is pushing the envelope of what’s possible in eye health, paving the way for groundbreaking solutions that promise to enhance the lives of millions globally. The eyes of the world are indeed on them as they continue to unfold the future of ophthalmology at the ASCRS 2024.
*enVista Envy is pending PMA approval and is not approved for sale in the United States or its territories.